Skip to Main Content
TABLE 2

Effect of Ca2+ channel antagonists on hormone release from rat islets

Glucose (mmol/l)Insulin (ng · islet−1 · h−1)
Somatostatin (pmol · islet−1 · h−1)
Glucagon (pg · islet−1 · h−1)
120120120
Control 0.49 ± 0.04 10.39 ± 0.7 4.30 ± 0.6 17.82 ± 2.3 36.85 ± 2.3 19.79 ± 1.2 
2.5 μmol/l isradipine 0.47 ± 0.05 1.72 ± 0.2* 3.65 ± 0.5 14.06 ± 1.3 34.10 ± 2.5 28.98 ± 3.6§ 
0.1 μmol/l SNX482 0.42 ± 0.04 8.87 ± 0.9 2.92 ± 0.3 9.37 ± 1.3 39.75 ± 3.9 23.91 ± 3.3 
0.1 μmol/l ω-conotoxin GVIA 0.44 ± 0.04 9.40 ± 0.6 3.44 ± 0.5 14.13 ± 2.6 17.03 ± 2.9* 16.06 ± 1.1 
Glucose (mmol/l)Insulin (ng · islet−1 · h−1)
Somatostatin (pmol · islet−1 · h−1)
Glucagon (pg · islet−1 · h−1)
120120120
Control 0.49 ± 0.04 10.39 ± 0.7 4.30 ± 0.6 17.82 ± 2.3 36.85 ± 2.3 19.79 ± 1.2 
2.5 μmol/l isradipine 0.47 ± 0.05 1.72 ± 0.2* 3.65 ± 0.5 14.06 ± 1.3 34.10 ± 2.5 28.98 ± 3.6§ 
0.1 μmol/l SNX482 0.42 ± 0.04 8.87 ± 0.9 2.92 ± 0.3 9.37 ± 1.3 39.75 ± 3.9 23.91 ± 3.3 
0.1 μmol/l ω-conotoxin GVIA 0.44 ± 0.04 9.40 ± 0.6 3.44 ± 0.5 14.13 ± 2.6 17.03 ± 2.9* 16.06 ± 1.1 

Data are means ± SE of 8 experiments. Hormone release was measured at 1 and 20 mmol/l glucose in the absence and presence of isradipine, SNX482, and ω-conoxotin GVIA as indicated. Statistical significance is evaluated against the control at the same glucose concentration.

*

P < 0.001;

P < 0.01;

NS;

§

P < 0.05.

Close Modal

or Create an Account

Close Modal
Close Modal